147111-30-6

Usage

Uses

Used in Chemical Reactions and Synthesis Processes:
2-(4-bromophenyl)ethanethioamide is used as a key intermediate for the synthesis of various organic compounds and pharmaceuticals, leveraging its thioamide functional group to facilitate specific chemical transformations and reactions.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-(4-bromophenyl)ethanethioamide is utilized as a starting material or building block for the development of potential therapeutic agents, owing to its unique chemical properties and reactivity.
Used in Research Laboratories:
2-(4-bromophenyl)ethanethioamide is employed as a research compound in laboratories to study the properties and behaviors of thioamides, contributing to the understanding of their chemical characteristics and potential applications in various fields.
Used in Industrial Applications:
2-(4-bromophenyl)ethanethioamide has the potential for various industrial applications, such as in the production of specialty chemicals, agrochemicals, and materials science, making it a valuable chemical compound with diverse uses across different sectors.

Upstream product

• 16532-79-9 4-Bromophenylacetonitrile 
• 74860-13-2 4-bromobenzeneacetamide 
• 37859-24-8 2-(4-bromophenyl)acetyl chloride 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 

Downstream Products

• 344255-80-7 [2-(4-Bromo-benzyl)-thiazol-4-yl]-acetic acid ethyl ester 
• 84863-90-1 2-[2-(4-Bromo-benzyl)-thiazol-4-yl]-acetamide 
• 78764-59-7 3-[2-(4-Bromo-benzyl)-thiazol-4-yl]-4-hydroxy-pyrrole-2,5-dione 
• 1318758-61-0 2-(4-bromobenzyl)-4-methylthiazole-5-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

Optimization of Novel 1-Methyl-1 H-Pyrazole-5-carboxamides Leads to High Potency Larval Development Inhibitors of the Barber's Pole Worm

A phenotypic screen of a diverse library of small molecules for inhibition of the development of larvae of the parasitic nematode Haemonchus contortus led to the identification of a 1-methyl-1H-pyrazole-5-carboxamide derivative with an IC50 of 0.29 μM. Medicinal chemistry optimization targeted modifications on the left-hand side (LHS), middle section, and right-hand side (RHS) of the scaffold in order to elucidate the structure-activity relationship (SAR). Strong SAR allowed for the iterative and directed assembly of a focus set of 64 analogues, from which compound 60 was identified as the most potent compound, inhibiting the development of the fourth larval (L4) stage with an IC50 of 0.01 μM. In contrast, only 18% inhibition of the mammary epithelial cell line MCF10A viability was observed, even at concentrations as high as 50 μM.

GLUCOSE TRANSPORT INHIBITORS

The present invention relates to quinoline-4-carboxamide derivatives of Formula (I) that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds,